Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carmelo Scarpignato

Showing results (71-80 of 125) with videos related to

Pageof 13
Sort By:
Nature Reviews. Disease Primers|March 29, 2020
Colonic diverticular diseaseAntonio Tursi, Carmelo Scarpignato, Lisa L Strate, et al.
Nature Reviews. Disease Primers|June 20, 2020
Author Correction: Colonic diverticular diseaseAntonio Tursi, Carmelo Scarpignato, Lisa L Strate, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|March 10, 2019
The "DICA" endoscopic classification for diverticular disease of the colon shows a significant interobserver agreement among community endoscopistsAntonio Tursi, Giovanni Brandimarte, Francesco di Mario, et al.
Journal of Clinical Gastroenterology|September 14, 2016
Mesalazine for the Treatment of Symptomatic Uncomplicated Diverticular Disease of the Colon and for Primary Prevention of Diverticulitis: A Systematic Review of Randomized Clinical TrialsMarcello Picchio, Walter Elisei, Giovanni Brandimarte, et al.
Journal of Gastroenterology and Hepatology|September 30, 2017
Searching for a definition for pharmacologically refractory constipation: A systematic reviewAlex Yu Sen Soh, Jin-Yong Kang, Kewin Tien Ho Siah, et al.
Gastroenterology|December 24, 2016
Rifaximin Reduces the Number and Severity of Intestinal Lesions Associated With Use of Nonsteroidal Anti-Inflammatory Drugs in HumansCarmelo Scarpignato, Werner Dolak, Angel Lanas, et al.
Journal of Clinical Pharmacology|December 22, 2021
A Population Pharmacokinetic Model of Vonoprazan: Evaluating the Effects of Race, Disease Status, and Other Covariates on ExposureCarmelo Scarpignato, Eckhard Leifke, Neila Smith, et al.
International Journal of Clinical Pharmacy|March 23, 2016
Adherence with regulatory resolutions on prevention of NSAIDS-related gastrointestinal injury in ItalySabrina Montagnani, Marco Tuccori, Arianna Testi, et al.
Alimentary Pharmacology & Therapeutics|April 17, 2023
A translational pharmacokinetic/pharmacodynamic approach supports optimal vonoprazan dosing for erosive oesophagitis and Helicobacter pylori infectionCarmelo Scarpignato, Colin W Howden, Eckhard Leifke, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 30, 2026
Development and Use of a Population Pharmacokinetic Model for Characterizing the Pharmacokinetics of Vonoprazan in Pediatric PatientsDarcy J Mulford, Axel Facius, Galen Witt, et al.
Pageof 13

Showing results (71-80 of 125) with videos related to

Sort By:
Pageof 13
Nature Reviews. Disease Primers|March 29, 2020
Colonic diverticular diseaseAntonio Tursi, Carmelo Scarpignato, Lisa L Strate, et al.
Nature Reviews. Disease Primers|June 20, 2020
Author Correction: Colonic diverticular diseaseAntonio Tursi, Carmelo Scarpignato, Lisa L Strate, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|March 10, 2019
The "DICA" endoscopic classification for diverticular disease of the colon shows a significant interobserver agreement among community endoscopistsAntonio Tursi, Giovanni Brandimarte, Francesco di Mario, et al.
Journal of Clinical Gastroenterology|September 14, 2016
Mesalazine for the Treatment of Symptomatic Uncomplicated Diverticular Disease of the Colon and for Primary Prevention of Diverticulitis: A Systematic Review of Randomized Clinical TrialsMarcello Picchio, Walter Elisei, Giovanni Brandimarte, et al.
Journal of Gastroenterology and Hepatology|September 30, 2017
Searching for a definition for pharmacologically refractory constipation: A systematic reviewAlex Yu Sen Soh, Jin-Yong Kang, Kewin Tien Ho Siah, et al.
Gastroenterology|December 24, 2016
Rifaximin Reduces the Number and Severity of Intestinal Lesions Associated With Use of Nonsteroidal Anti-Inflammatory Drugs in HumansCarmelo Scarpignato, Werner Dolak, Angel Lanas, et al.
Journal of Clinical Pharmacology|December 22, 2021
A Population Pharmacokinetic Model of Vonoprazan: Evaluating the Effects of Race, Disease Status, and Other Covariates on ExposureCarmelo Scarpignato, Eckhard Leifke, Neila Smith, et al.
International Journal of Clinical Pharmacy|March 23, 2016
Adherence with regulatory resolutions on prevention of NSAIDS-related gastrointestinal injury in ItalySabrina Montagnani, Marco Tuccori, Arianna Testi, et al.
Alimentary Pharmacology & Therapeutics|April 17, 2023
A translational pharmacokinetic/pharmacodynamic approach supports optimal vonoprazan dosing for erosive oesophagitis and Helicobacter pylori infectionCarmelo Scarpignato, Colin W Howden, Eckhard Leifke, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 30, 2026
Development and Use of a Population Pharmacokinetic Model for Characterizing the Pharmacokinetics of Vonoprazan in Pediatric PatientsDarcy J Mulford, Axel Facius, Galen Witt, et al.
Pageof 13